Singapore-based firm on track to commercialise cancer drug
Tessa Therapeutics teams up with California institute to run cancer-therapy trial, commercial launch expected in 2020
Singapore
SCIENTISTS are now a step closer to turning cancer patients' own immune cells (T-cells) against the tumours in their bodies - and possibly finding a cure for the dreaded disease.
A Singapore-based biotechnology firm has emerged ahead of the very crowded research field of T-cell immunotherapy, by conducting the world's first US Food and Drug Administration (FDA) Phase Three cancer T-cell therapy trial involving a number of hospitals and treatment centres across the world.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
International
China says Hamas and Fatah express will for reconciliation
US consumer confidence at lowest level since 2022
Record gold prices boost recycling: WGC
Malaysian fast food operator QSR shelves IPO plans amid boycott campaign: sources
WHO warns of bird flu risk spreading to cows outside US
Sri Lanka’s key inflation rate rises to 1.5% in April